Filing Flows › Neurocrine Biosciences (NBIX) › How it makes money
How Neurocrine Biosciences (NBIX) makes money
Neurocrine Biosciences (NBIX) made $1.1B of revenue in the third quarter 2026 (Q3 2026), +41% from a year earlier. Of every dollar of revenue, 30¢ was left as operating profit, 18¢ was left as net earnings.
Drawing the Sankey…
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $1.1B | 100.0% |
| Operating profit | $331M | 29.5% |
| Income tax | $77.2M | 6.9% |
| Net earnings | $206M | 18.4% |
| Operating cash flow | $395M | 35.2% |
| Free cash flow | $384M | 34.2% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $1.1B | +41% |
| Q2 2026 | $959M | +40% |
| Q1 2026 | $814M | +42% |
| Q4 2025 | $806M | +28% |
| Q3 2025 | $795M | +28% |
| Q2 2025 | $688M | +16% |
| Q1 2025 | $573M | +11% |
From Neurocrine Biosciences' 10-Q filed Nov 2, 2026 (on EDGAR).
Questions
How does Neurocrine Biosciences make money?
Neurocrine Biosciences (NBIX) made $1.1B of revenue in the third quarter 2026 (Q3 2026), +41% from a year earlier. Of every dollar of revenue, 30¢ was left as operating profit, 18¢ was left as net earnings.
What is Neurocrine Biosciences' profit margin?
Net earnings were $206M, 18.4% of revenue, in the third quarter 2026; the operating margin was 29.5%.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.